Lack of susceptibility of bicyclic nucleoside analogs, highly potent inhibitors of varicella-zoster virus, to the catabolic action of thymidine phosphorylase and dihydropyrimidine dehydrogenase

被引:28
作者
Balzarini, J
Sienaert, R
Liekens, S
Van Kuilenburg, A
Carangio, A
Esnouf, R
De Clercq, E
McGuigan, C
机构
[1] Katholieke Univ Leuven, Rega Inst Med Res, B-3000 Louvain, Belgium
[2] Univ Amsterdam, Acad Med Ctr, Lab Genet Metab Dis, NL-1105 AZ Amsterdam, Netherlands
[3] Univ Wales Coll Cardiff, Welsh Sch Pharm, Cardiff, S Glam, Wales
[4] Wellcome Trust Ctr Human Genet, Div Struct Biol, Oxford, England
关键词
D O I
10.1124/mol.61.5.1140
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The susceptibility of the bicyclic nucleoside analogs (BCNAs), highly potent and selective inhibitors of varicella-zoster virus (VZV), to the enzymes involved in nucleoside/nucleobase catabolism has been investigated in comparison with the established anti-VZV agent (E)-5-(2-bromovinyl)-2'-deoxyuridine [BVDU; brivudine (Zostex)]. Whereas human and bacterial thymidine phosphorylases (TPases) efficiently converted BVDU to its antivirally inactive free base (E)-5-(2-bromovinyl) uracil (BVU), BCNAs showed no evidence of conversion to the free base in the presence of these enzymes. The lack of substrate affinity of TPase for the BCNAs could be rationalized by computer-assisted molecular modeling of the BCNAs in the TPase active site. Moreover, in contrast with BVU, which is a potent and selective inhibitor of dihydropyrimidine dehydrogenase (DPD) (50% inhibitory concentration; 10 muM in the presence of a 25 muM concentration of the natural substrate thymine), the free base (Cf 1381; 6-octyl-2,3-dihydrofuro[2,3-d]pyrimidin-2-one) of BCNA (Cf 1368; 3-(2'-deoxy-beta-D-ribofuranosyl)-6-octyl-2,3-dihydrofuro[ 2,3-d] pyrimidin-2-one) and the free base Cf 2200 [6-(4-n-pentylphenyl)-2,3-dihydrofuro[2,3-d]pyrimidin-2-one] of BCNA (Cf 1743; 3-(2'-deoxy-beta-D-ribofuranosyl)-6-(4-n-pentylphenyl)-2,3- dihydrofuro[ 2,3-d] pyrimidin-2-one) did not inhibit the DPD-catalyzed catabolic reaction of pyrimidine bases (i.e., thymine) and pyrimidine base analogs [i.e., 5-fluorouracil (FU)] at a concentration of 250 muM. Consequently, whereas BVU caused a dramatic rise of FU levels in FU-treated mice, the BCNAs did not affect FU levels in such mice. From our data it is evident that BCNAs represent highly stable anti-VZV compounds that are not susceptible to breakdown by nucleoside/nucleobase catabolic enzymes and are not expected to interfere with cellular catabolic processes such as those involved in FU catabolism.
引用
收藏
页码:1140 / 1145
页数:6
相关论文
共 23 条
[1]  
BALZARINI J, 2002, IN PRESS J ANTIMICRO
[2]  
BALZARINI J, 2002, IN PRESS BIOCH BIOPH
[3]  
de Clercq Erik, 1997, P1
[4]   THE ANTIVIRAL SPECTRUM OF (E)-5-(2-BROMOVINYL)-2'-DEOXYURIDINE [J].
DECLERCQ, E .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1984, 14 :85-95
[5]  
DECLERCQ E, 1979, P NATL ACAD SCI USA, V76, P2947, DOI 10.1073/pnas.76.6.2947
[6]  
DECLERCQ E, 2001, IN PRESS RECENT ADV
[7]   PHOSPHOROLYSIS OF (E)-5-(2-BROMOVINYL)-2'-DEOXYURIDINE (BVDU) AND OTHER 5-SUBSTITUTED-2'-DEOXYURIDINES BY PURIFIED HUMAN THYMIDINE PHOSPHORYLASE AND INTACT BLOOD-PLATELETS [J].
DESGRANGES, C ;
RAZAKA, G ;
RABAUD, M ;
BRICAUD, H ;
BALZARINI, J ;
DECLERCQ, E .
BIOCHEMICAL PHARMACOLOGY, 1983, 32 (23) :3583-3590
[8]  
DESGRANGES C, 1986, CANCER RES, V46, P1094
[9]   REGENERATION OF THE ANTIVIRAL DRUG (E)-5-(2-BROMOVINYL)-2'-DEOXYURIDINE INVIVO [J].
DESGRANGES, C ;
RAZAKA, G ;
DROUILLET, F ;
BRICAUD, H ;
HERDEWIJN, P ;
DECLERCQ, E .
NUCLEIC ACIDS RESEARCH, 1984, 12 (04) :2081-2090
[10]   Sorivudine and 5-fluorouracil; a clinically significant drug-drug interaction due to inhibition of dihydropyrimidine dehydrogenase [J].
Diasio, RB .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 46 (01) :1-4